Do analysts rate BOLD or GLSI?

Greenwich LifeSciences has a consensus price target of $57.00, indicating a potential upside of 230.63%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings and valuation, BOLD or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is BOLD or GLSI more profitable?

Boundless Bio's return on equity of -65.05% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -65.05% -41.14% Greenwich LifeSciences N/A -833.03% -317.44%

Do analysts rate BOLD or AKBA?

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 330.54%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation & earnings, CAPR or BOLD?

Capricor Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A Boundless Bio N/A N/A -$58.20M -$2.86 N/A

Is CAPR or BOLD more profitable?

Capricor Therapeutics' return on equity of -59.27% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Boundless Bio N/A -65.05% -41.14%

Do analysts rate ALEC or BOLD?

Alector currently has a consensus price target of $3.63, indicating a potential upside of 77.26%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALEC or BOLD more profitable?

Boundless Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. Boundless Bio's return on equity of -65.05% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Boundless Bio N/A -65.05% -41.14%

Do analysts prefer CGEN or BOLD?

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 107.90%. Given Compugen's stronger consensus rating and higher probable upside, research analysts clearly believe Compugen is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CGEN or BOLD more profitable?

Compugen has a net margin of 47.56% compared to Boundless Bio's net margin of 0.00%. Compugen's return on equity of 42.57% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.56% 42.57% 26.13% Boundless Bio N/A -65.05% -41.14%

Boundless Bio (BOLD) Competitors

$2.79 +0.01 (+0.36%)

As of 12:41 PM Eastern

Compare

BOLD vs. GLSI, AKBA, CAPR, ALEC, and CGEN

Should you buy Boundless Bio stock or one of its competitors? Boundless Bio's main competitors and comparable companies include Greenwich LifeSciences (GLSI), Akebia Therapeutics (AKBA), Capricor Therapeutics (CAPR), Alector (ALEC), and Compugen (CGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Boundless Bio compare to Greenwich LifeSciences?

Boundless Bio (NASDAQ:BOLD) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Boundless Bio has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Boundless Bio's return on equity of -65.05% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-65.05%	-41.14%
Greenwich LifeSciences	N/A	-833.03%	-317.44%

Greenwich LifeSciences has a consensus price target of $57.00, indicating a potential upside of 230.63%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Greenwich LifeSciences had 4 more articles in the media than Boundless Bio. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat Greenwich LifeSciences' score of 1.41 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Positive
Greenwich LifeSciences	Positive

Summary

Greenwich LifeSciences beats Boundless Bio on 9 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Akebia Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 330.54%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Boundless Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Boundless Bio's return on equity of -65.05% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-65.05%	-41.14%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Boundless Bio has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

In the previous week, Akebia Therapeutics had 10 more articles in the media than Boundless Bio. MarketBeat recorded 11 mentions for Akebia Therapeutics and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat Akebia Therapeutics' score of -0.02 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Positive
Akebia Therapeutics	Neutral

33.9% of Akebia Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Boundless Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Akebia Therapeutics	$219.06M	1.10	-$5.34M	-$0.11	N/A

Summary

Akebia Therapeutics beats Boundless Bio on 10 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Capricor Therapeutics had 55 more articles in the media than Boundless Bio. MarketBeat recorded 56 mentions for Capricor Therapeutics and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat Capricor Therapeutics' score of 0.00 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Capricor Therapeutics	Neutral
Boundless Bio	Positive

Capricor Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

Capricor Therapeutics' return on equity of -59.27% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Boundless Bio	N/A	-65.05%	-41.14%

Capricor Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 23.1% of Boundless Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Capricor Therapeutics presently has a consensus price target of $29.15, suggesting a potential upside of 340.00%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Capricor Therapeutics beats Boundless Bio on 8 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Alector?

Alector (NASDAQ:ALEC) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Alector had 13 more articles in the media than Boundless Bio. MarketBeat recorded 14 mentions for Alector and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat Alector's score of -0.16 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Neutral
Boundless Bio	Positive

Boundless Bio has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	10.85	-$142.93M	-$1.10	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

Boundless Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. Boundless Bio's return on equity of -65.05% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Boundless Bio	N/A	-65.05%	-41.14%

Alector has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

Alector currently has a consensus price target of $3.63, indicating a potential upside of 77.26%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 23.1% of Boundless Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Alector beats Boundless Bio on 8 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Compugen?

Compugen (NASDAQ:CGEN) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 107.90%. Given Compugen's stronger consensus rating and higher probable upside, research analysts clearly believe Compugen is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Compugen has higher revenue and earnings than Boundless Bio. Boundless Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.13	$35.34M	$0.38	6.33
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

In the previous week, Compugen had 3 more articles in the media than Boundless Bio. MarketBeat recorded 4 mentions for Compugen and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 beat Compugen's score of 1.11 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Compugen	Positive
Boundless Bio	Positive

Compugen has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compugen has a net margin of 47.56% compared to Boundless Bio's net margin of 0.00%. Compugen's return on equity of 42.57% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Boundless Bio	N/A	-65.05%	-41.14%

Summary

Compugen beats Boundless Bio on 14 of the 16 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.50M	$3.70B	$6.98B	$13.03B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-0.98	10.37	269.56	25.24
Price / Sales	N/A	1,289.70	596.34	100.74
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.63	17.36	13.02	6.32
Net Income	-$58.20M	-$13.32M	$3.45B	$347.92M
7 Day Performance	-3.46%	0.73%	0.69%	0.91%
1 Month Performance	13.41%	0.52%	1.32%	0.89%
1 Year Performance	141.56%	54.37%	66.86%	20.28%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	1.8188 of 5 stars	$2.79 +0.4%	N/A	+136.6%	$63.50M	N/A	N/A	64	Earnings Report
GLSI Greenwich LifeSciences	3.374 of 5 stars	$16.38 -3.2%	$57.00 +248.0%	+39.0%	$248.35M	N/A	N/A	3	Positive News Earnings Report Analyst Forecast
AKBA Akebia Therapeutics	1.8376 of 5 stars	$0.87 -2.6%	$3.75 +331.2%	-73.6%	$247.51M	$236.20M	N/A	430
CAPR Capricor Therapeutics	2.9169 of 5 stars	$4.21 +0.5%	$29.15 +592.4%	-49.3%	$242.65M	$22.27M	N/A	101	Trending News Earnings Report Analyst Upgrade Gap Up High Trading Volume
ALEC Alector	1.7356 of 5 stars	$2.04 -5.1%	$3.63 +77.7%	-6.4%	$240.06M	$21.05M	N/A	270	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. GLSI, AKBA, CAPR, ALEC, and CGEN

How does Boundless Bio compare to Greenwich LifeSciences?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Summary

How does Boundless Bio compare to Capricor Therapeutics?

Summary

How does Boundless Bio compare to Alector?

Summary

How does Boundless Bio compare to Compugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. GLSI, AKBA, CAPR, ALEC, and CGEN

How does Boundless Bio compare to Greenwich LifeSciences?

Do insiders & institutionals have more ownership in BOLD or GLSI?

Which has stronger earnings and valuation, BOLD or GLSI?

Which has more risk & volatility, BOLD or GLSI?

Is BOLD or GLSI more profitable?

Do analysts rate BOLD or GLSI?

Does the media prefer BOLD or GLSI?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Do analysts rate BOLD or AKBA?

Is BOLD or AKBA more profitable?

Which has more risk and volatility, BOLD or AKBA?

Does the media prefer BOLD or AKBA?

Do institutionals & insiders believe in BOLD or AKBA?

Which has better earnings and valuation, BOLD or AKBA?

Summary

How does Boundless Bio compare to Capricor Therapeutics?

Does the media favor CAPR or BOLD?

Which has more volatility and risk, CAPR or BOLD?

Is CAPR or BOLD more profitable?

Which has better valuation & earnings, CAPR or BOLD?

Do insiders and institutionals hold more shares of CAPR or BOLD?

Do analysts prefer CAPR or BOLD?

Summary

How does Boundless Bio compare to Alector?

Does the media favor ALEC or BOLD?

Which has better valuation and earnings, ALEC or BOLD?

Is ALEC or BOLD more profitable?

Which has more volatility & risk, ALEC or BOLD?

Do analysts rate ALEC or BOLD?

Do institutionals & insiders have more ownership in ALEC or BOLD?

Summary

How does Boundless Bio compare to Compugen?

Do analysts prefer CGEN or BOLD?

Which has higher valuation and earnings, CGEN or BOLD?

Does the media prefer CGEN or BOLD?

Which has more risk and volatility, CGEN or BOLD?

Do insiders and institutionals believe in CGEN or BOLD?

Is CGEN or BOLD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools